68 and 77 degrees F)
Atropisol :
- Store at controlled room temperature (between 68 and 77 degrees F)
Isopto Atropine:
- Store at controlled room temperature (between 68 and 77 degrees F)
Ocu-Tropine:
- Store at room temperature (between 59 to 86 degrees F
CONTRAINDICATIONS / PRECAUTIONS
General Information
Atropine should not be used in patients with known atropine or other belladonna alkaloids hypersensitivity because they may develop an allergic or other adverse reaction, including anaphylaxis. NOTE: Intense flushing of the face (blush area) and trunk may occur following parenteral injection of atropine. This is called the 'atropine flush' and is not harmful when it occurs.
Parenteral atropine products may contain sodium metabisulfite. These formulations should be used with caution in patients with known sulfite hypersensitivity in which sulfites may precipitate an allergic reaction.
The primary protection against exposure to chemical nerve agents and insecticide poisoning is a protective garment including a mask designed for this use. Do not rely solely on the availability of antidotes such as atropine (i.e., AtroPen) and pralidoxime to provide complete protection from chemical nerve agent and insecticide poisoning. Immediate evacuation from the contaminated site is essential. Medical help should be sought. Decontamination of the poisoned individual should occur as quickly as possible. Clothing should be removed and the hair and skin washed thoroughly with sodium bicarbonate or alcohol. Provide symptomatic support as needed (i.e., respiration, bronchial secretion suction).
Driving or operating machinery
Because of the potential for toxicity, systemic atropine should not be taken in amounts above prescription limits. Because atropine may cause blurred vision, drowsiness, or dizziness, patients should use caution when driving or operating machinery until they are aware of the effects of the drug.
Acute myocardial infarction, angina, bleeding, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hyperthyroidism, mitral stenosis, myocardial infarction, tachycardia, thyrotoxicosis
Atropine may alter heart rate, with the predominant clinical effect being tachycardia. This increase in heart rate results in increased oxygen demand on the heart and can exacerbate myocardial ischemia. To avoid these adverse cardiac events, the total dose of atropine should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg). Atropine should be used with caution in patients with a recent myocardial infarction or a known cardiac disease where an increase in heart rate could be detrimental (i.e., cardiac arrhythmias, congestive heart failure, coronary artery disease, angina, or other cardiac instability). Atropine should be used with caution during acute myocardial infarction because the drug can potentiate arrhythmias. Increased heart rate is also undesirable in patients with hyperthyroidism (thyrotoxicosis) or cardiovascular instability in acute hemorrhage (bleeding). Antimuscarinics should be used with caution in patients with mitral stenosis, since tachycardia could exacerbate the clinical symptoms of this condition. Antimuscarinics should be used with caution in patients with hypertension, since they have some actions on the heart that can exacerbate this condition.
Heart transplant
Atropine may be used to treat bradycardia with caution after heart |
